Heron Therapeutics Inc HRTX
NASDAQ · United States · Health Technology
$0.3476-0.01 (-2.33%)
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Company navigates mixed Q2 results with strong APONVIE growth, while withdrawing guidance due to CINVANTI patent challenges and exploring strategic alternatives.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Heron Therapeutics reported modest second-quarter revenue growth, but uncertainty around potential generic CINVANTI competition and a strategic alternatives process prompted the company to withdraw its full-year 2026 guidance. Key Investor TakeawaysHeron Therapeutics (NASDAQ:HRTX) reported Q2 2026 total net revenue of $37.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.